Literature DB >> 31187193

Left heart function in COPD : Impact of lung deflation.

N Struß1, J Bauersachs2, T Welte3,4, J M Hohlfeld5,6,7.   

Abstract

Chronic obstructive pulmonary disease (COPD) primarily affects the lungs; however, cardiovascular conditions are among the most common extrapulmonary comorbidities. Besides shared risk factors such as cigarette smoking, pathophysiological connections between the lung and the heart have been identified as mediators of reduced cardiac output. Recent research has focused on hyperinflation of the lung as a pulmonary cause for heart dysfunction. Hyperinflation is a typical lung abnormality seen in COPD; it is characterized by increased residual volume, intrathoracic gas volume, and total lung capacity while vital capacity is decreased. The degree of hyperinflation with airway obstruction is inversely related to left ventricular filling, stroke volume, and cardiac output. The underlying mechanisms are assumed to be compression of the pulmonary veins and thus reduced preload of the left heart as well as decreased pulmonary microvascular blood flow due to compression of the pulmonary vasculature. Treatment with a dual bronchodilator antagonizes this detrimental lung-heart unbalance effectively: Pulmonary blood flow, left ventricular end-diastolic volume, and stroke volume increase in COPD patients without cardiac abnormalities. Similar effects, yet less pronounced, were reported with single bronchodilator therapy. Future work needs to investigate whether these promising findings can be reproduced in COPD patients with cardiovascular diseases.

Entities:  

Keywords:  Bronchodilator effect; Cardiovascular disease; Hyperinflation; Left ventricular function; Pulmonary disease, chronic obstructive

Mesh:

Substances:

Year:  2019        PMID: 31187193     DOI: 10.1007/s00059-019-4816-5

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  26 in total

Review 1.  Neurohumoral activation as a link to systemic manifestations of chronic lung disease.

Authors:  Stefan Andreas; Stefan D Anker; Paul D Scanlon; Virend K Somers
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

2.  Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function.

Authors:  A J Coats; S Adamopoulos; A Radaelli; A McCance; T E Meyer; L Bernardi; P L Solda; P Davey; O Ormerod; C Forfar
Journal:  Circulation       Date:  1992-06       Impact factor: 29.690

3.  Marked sympathetic activation in patients with chronic respiratory failure.

Authors:  S Heindl; M Lehnert; C P Criée; G Hasenfuss; S Andreas
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

4.  Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.

Authors:  Mario Cazzola; Antonio Mantero; Pierachille Santus; Paolo Carlucci; Michele Mondoni; Laura Bosotti; Stefano Centanni
Journal:  Pulm Pharmacol Ther       Date:  2006-03-06       Impact factor: 3.410

Review 5.  Mortality in COPD: Role of comorbidities.

Authors:  D D Sin; N R Anthonisen; J B Soriano; A G Agusti
Journal:  Eur Respir J       Date:  2006-12       Impact factor: 16.671

6.  Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation.

Authors:  Henrik Watz; Benjamin Waschki; Trhorsten Meyer; Gunther Kretschmar; Anne Kirsten; Martin Claussen; Helgo Magnussen
Journal:  Chest       Date:  2010-02-26       Impact factor: 9.410

7.  Percent emphysema, airflow obstruction, and impaired left ventricular filling.

Authors:  R Graham Barr; David A Bluemke; Firas S Ahmed; J Jeffery Carr; Paul L Enright; Eric A Hoffman; Rui Jiang; Steven M Kawut; Richard A Kronmal; João A C Lima; Eyal Shahar; Lewis J Smith; Karol E Watson
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

8.  Slow breathing reduces sympathoexcitation in COPD.

Authors:  T Raupach; F Bahr; P Herrmann; L Luethje; K Heusser; G Hasenfuss; L Bernardi; S Andreas
Journal:  Eur Respir J       Date:  2008-04-02       Impact factor: 16.671

Review 9.  Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications.

Authors:  Guido Grassi; Gino Seravalle; Fosca Quarti-Trevano; Raffaella Dell'oro
Journal:  Curr Vasc Pharmacol       Date:  2009-04       Impact factor: 2.719

10.  Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.

Authors:  Kai M Beeh; Dave Singh; Lilla Di Scala; Anton Drollmann
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-31
View more
  2 in total

1.  Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET.

Authors:  Peter Alter; Jan Orszag; Christina Kellerer; Kathrin Kahnert; Tim Speicher; Henrik Watz; Robert Bals; Tobias Welte; Claus F Vogelmeier; Rudolf A Jörres
Journal:  ERJ Open Res       Date:  2020-07-27

2.  Influence of Comorbidities on the Survival of COPD Patients According to Phenotypes.

Authors:  Zichen Ji; Julio Hernández-Vázquez; Irene Milagros Domínguez-Zabaleta; Ziyi Xia; José María Bellón-Cano; Virginia Gallo-González; Ismael Ali-García; Carmen Matesanz-Ruiz; Ana López-de-Andrés; Rodrigo Jiménez-García; María Jesús Buendía-García; Ángela Gómez-Sacristán; Walther Iván Girón-Matute; Luis Puente-Maestu; Javier de Miguel-Díez
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.